1
|
Scotland S, Saland E, Skuli N, de Toni F, Boutzen H, Micklow E, Sénégas I, Peyraud R, Peyriga L, Théodoro F, Dumon E, Martineau Y, Danet-Desnoyers G, Bono F, Rocher C, Levade T, Manenti S, Junot C, Portais JC, Alet N, Récher C, Selak MA, Carroll M, Sarry JE. Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells. Leukemia 2013; 27:2129-38. [PMID: 23568147 PMCID: PMC10869165 DOI: 10.1038/leu.2013.107] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2012] [Revised: 03/29/2013] [Accepted: 04/02/2013] [Indexed: 12/16/2022]
Abstract
Previous reports demonstrate that metformin, an anti-diabetic drug, can decrease the risk of cancer and inhibit cancer cell growth. However, its mechanism in cancer cells is still unknown. Metformin significantly blocks cell cycle and inhibits cell proliferation and colony formation of leukemic cells. However, the apoptotic response to metformin varies. Furthermore, daily treatment with metformin induces apoptosis and reduces tumor growth in vivo. While metformin induces early and transient activation of AMPK, inhibition of AMPKα1/2 does not abrogate anti-proliferative or pro-apoptotic effects of metformin. Metformin decreases electron transport chain complex I activity, oxygen consumption and mitochondrial ATP synthesis, while stimulating glycolysis for ATP and lactate production, pentose phosphate pathway for purine biosynthesis, fatty acid metabolism, as well as anaplerotic and mitochondrial gene expression. Importantly, leukemic cells with high basal AKT phosphorylation, glucose consumption or glycolysis exhibit a markedly reduced induction of the Pasteur effect in response to metformin and are resistant to metformin-induced apoptosis. Accordingly, glucose starvation or treatment with deoxyglucose or an AKT inhibitor induces sensitivity to metformin. Overall, metformin elicits reprogramming of intermediary metabolism leading to inhibition of cell proliferation in all leukemic cells and apoptosis only in leukemic cells responding to metformin with AKT phosphorylation and a strong Pasteur effect.
Collapse
Affiliation(s)
- S Scotland
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - E Saland
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - N Skuli
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - F de Toni
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - H Boutzen
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - E Micklow
- Department of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - I Sénégas
- Sanofi R&D, Early-to-Candidate Unit, Toulouse, France
| | - R Peyraud
- Université de Toulouse, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques et des Procédés, Toulouse, France
| | - L Peyriga
- Université de Toulouse, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques et des Procédés, Toulouse, France
- CNRS, UMR5504, Toulouse, France
| | - F Théodoro
- CEA/DSV/iBiTec-S/SPI, Bâtiment 136, CEA/Saclay, Gif-sur-Yvette, Fontenay-aux-Roses, France
| | - E Dumon
- Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, Université de Bordeaux, Bordeaux, France
| | - Y Martineau
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - G Danet-Desnoyers
- Department of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - F Bono
- Sanofi R&D, Early-to-Candidate Unit, Toulouse, France
| | - C Rocher
- Institut de Biochimie et Génétique Cellulaires, CNRS UMR 5095, Université de Bordeaux, Bordeaux, France
| | - T Levade
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - S Manenti
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| | - C Junot
- CEA/DSV/iBiTec-S/SPI, Bâtiment 136, CEA/Saclay, Gif-sur-Yvette, Fontenay-aux-Roses, France
| | - J-C Portais
- Université de Toulouse, INSA, UPS, INP, LISBP, Toulouse, France
- INRA, UMR792, Ingénierie des Systèmes Biologiques et des Procédés, Toulouse, France
- CNRS, UMR5504, Toulouse, France
| | - N Alet
- Sanofi R&D, Early-to-Candidate Unit, Toulouse, France
| | - C Récher
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
- Service d’Hématologie, CHU de Toulouse, Hôpital Purpan, Toulouse, France
| | - MA Selak
- Department of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - M Carroll
- Department of Medicine, Division of Hematology & Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - J-E Sarry
- INSERM, U1037, Cancer Research Center of Toulouse, CHU Purpan, Toulouse, France
- Université de Paul Sabatier, Toulouse III, Toulouse, France
| |
Collapse
|
2
|
Kunduzova O, Alet N, Delesque‐Touchard N, Millet L, Castan‐Laurell I, Muller C, Dray C, Schaeffer P, Herault JP, Savi P, Bono F, Valet P. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes. FASEB J 2008; 22:4146-53. [DOI: 10.1096/fj.07-104018] [Citation(s) in RCA: 87] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- O. Kunduzova
- Institut National de la Santé et de la Recherche Médicale (INSERM)U858ToulouseFrance
- Université de Toulouse, Institut de Médecine Moleculaire de RangueilIFR31ToulouseFrance
| | - N. Alet
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | | | - L. Millet
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | - I. Castan‐Laurell
- Institut National de la Santé et de la Recherche Médicale (INSERM)U858ToulouseFrance
- Université de Toulouse, Institut de Médecine Moleculaire de RangueilIFR31ToulouseFrance
| | - C. Muller
- Université de Toulouse, Institut de Médecine Moleculaire de RangueilIFR31ToulouseFrance
- Institut de Pharmacologie et de Biologie StructuraleCNRS UMR 5089ToulouseFrance
| | - C. Dray
- Institut National de la Santé et de la Recherche Médicale (INSERM)U858ToulouseFrance
- Université de Toulouse, Institut de Médecine Moleculaire de RangueilIFR31ToulouseFrance
| | - P. Schaeffer
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | - J. P. Herault
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | - P. Savi
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | - F. Bono
- Angiogenesis and Thrombosis DepartmentSanofi‐Aventis ResearchToulouseFrance
| | - P. Valet
- Institut National de la Santé et de la Recherche Médicale (INSERM)U858ToulouseFrance
- Université de Toulouse, Institut de Médecine Moleculaire de RangueilIFR31ToulouseFrance
| |
Collapse
|